Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

1. Merck KGaA to acquire SpringWorks for $3.9 billion. 2. Offer includes $47 per share, 26% premium over recent prices. 3. SWTX shares up 2% premarket; Merck shares up 1.5%. 4. Deal expected to close in H2 2025, pending regulatory approval. 5. Accretive to Merck's earnings pre-2027, enhancing focus on rare diseases.